Induction of CYP2D6 in pregnancy

被引:160
作者
Wadelius, M [1 ]
Darj, E [1 ]
Frenne, G [1 ]
Rane, A [1 ]
机构
[1] UNIV UPPSALA HOSP,DEPT OBSTET & GYNECOL,S-75185 UPPSALA,SWEDEN
关键词
D O I
10.1016/S0009-9236(97)90118-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Expression of the drug-metabolizing enzyme cytochrome P4502D6 (CYP2D6) is predominantly under genetic control, and enzyme-inducing drugs have little influence on its activity, We studied the activity of CYP2D6 during pregnancy, One hundred forty pregnant women were genotyped for CYP2D6, Seventeen of them (four poor metabolizers, seven heterozygous extensive metabolizers, and sis extensive metabolizers) were phenotyped with dextromethorphan in late pregnancy and 7 to 11 weeks after parturition, During pregnancy the dextromethorphan/dextrorphan metabolic ratio was significantly reduced (p = 0.0015) among homozygous and heterozygous extensive metabolizers, indicating increased CYP2D6 activity, In contrast, poor metabolizers showed an increased metabolic ratio during pregnancy. These results are consistent with previous findings of a marked increase in metabolism of the CYP2D6 substrate metoprolol during pregnancy, Both studies indicate an increase in CYP2D6 activity during pregnancy, which may be caused by an induction of the CYP2D6 enzyme.
引用
收藏
页码:400 / 407
页数:8
相关论文
共 32 条
  • [1] BROSEN K, 1993, CLIN INVESTIGATOR, V71, P1002
  • [2] The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans
    Capon, DA
    Bochner, F
    Kerry, N
    Mikus, G
    Danz, C
    Somogyi, AA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (03) : 295 - 307
  • [3] GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN
    DAHL, ML
    BERTILSSON, L
    [J]. PHARMACOGENETICS, 1993, 3 (02): : 61 - 70
  • [4] THE INFLUENCE OF ENZYME-INDUCTION ON POLYMORPHIC SPARTEINE OXIDATION
    EICHELBAUM, M
    MINESHITA, S
    OHNHAUS, EE
    ZEKORN, C
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (01) : 49 - 53
  • [5] EVIDENCE THAT ASPARTIC-ACID-301 IS A CRITICAL SUBSTRATE-CONTACT RESIDUE IN THE ACTIVE-SITE OF CYTOCHROME-P450 2D6
    ELLIS, SW
    HAYHURST, GP
    SMITH, G
    LIGHTFOOT, T
    WONG, MMS
    SIMULA, AP
    ACKLAND, MJ
    STERNBERG, MJE
    LENNARD, MS
    TUCKER, GT
    WOLF, CR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (49) : 29055 - 29058
  • [6] Gender differences in pharmacokinetics
    Gleiter, CH
    GundertRemy, U
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1996, 21 (02) : 123 - 128
  • [7] MOLECULAR-GENETICS OF THE DEBRISOQUIN-SPARTEINE POLYMORPHISM
    GONZALEZ, FJ
    MEYER, UA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (03) : 233 - 238
  • [8] IDENTIFICATION OF THE PRIMARY GENE DEFECT AT THE CYTOCHROME-P450 CYP2D LOCUS
    GOUGH, AC
    MILES, JS
    SPURR, NK
    MOSS, JE
    GAEDIGK, A
    EICHELBAUM, M
    WOLF, CR
    [J]. NATURE, 1990, 347 (6295) : 773 - 776
  • [9] GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
  • [10] EXPRESSION OF XENOBIOTIC-METABOLIZING CYTOCHROME-P450 FORMS IN HUMAN ADULT AND FETAL LIVER
    HAKKOLA, J
    PASANEN, M
    PURKUNEN, R
    SAARIKOSKI, S
    PELKONEN, O
    MAENPAA, J
    RANE, A
    RAUNIO, H
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 48 (01) : 59 - 64